Tandem Diabetes Care, Inc.
TNDM · Healthcare · $1.2B mkt cap · FY2025 filings · No moat ·
Doesn't clear the bar
The four filters
Median gross margin 51.8% over 10y, stable.
Median ROIC -30.8%, above the 9% hurdle in 0% of years.
Net debt/EBITDA n/ax, interest coverage -24x.
Owner earnings trend unclear, share count n/a.
Margin of safety
- Owner earnings (normalized)
- —
- Est. intrinsic value / share
- —
- Recent price
- $17.08
- Discount to value
- No price data
Conservative model: 9% discount rate, 0% assumed growth (capped at 4%), maintenance capex ≈ min(capex, D&A).
15 years of fundamentals
The business, in plain English
Tandem Diabetes Care, Inc. booked $1.0B of revenue in FY2025 in the Healthcare sector and kept 53.8% of it as gross profit — a solid-margin business by that measure. After every other cost, −20.2% of each revenue dollar reached the bottom line.
Across the filed record, revenue grew from $2.5M (FY2012) to $1.0B (FY2025) — about 58.8% a year compounded over 13 years.
It earned −39.5% on invested capital in FY2025, with a median of −36.8% across 12 filed years. The Returns on Capital filter above scores it 0/100.
The balance sheet carried $310.0M of total debt in FY2025. Balance-Sheet Safety scores it 28/100.
The share count rose 197.9% between FY2013 and FY2025 — existing owners have been diluted over the record. Capital Discipline scores it 44/100.
Put together: Pricing Power is the strongest of the four filters (72/100) and Returns on Capital the weakest (0/100), which is how TNDM lands at 36/100 — a None moat.
This breakdown is generated from the filed numbers and sub-scores above — no outside narrative, no estimates. Where a filing doesn’t disclose an input, the sentence that would need it is omitted instead of guessed.
Gaps in a line mean that item isn’t in TNDM’s filings for that year — the series is never interpolated or estimated. The Table view lists every filed value, including operating and net margins, total debt, and share count.
Moat Score history
Score history begins Jul 17, 2026 — the record builds from here and can’t be backfilled.
Tier changesSame-methodology crossings of the Wide / Narrow / Shallow bars
None yet — TNDM has read No moat for every logged capture since Jul 17, 2026.
Scores are logged append-only and never overwritten — this record can’t be backfilled, which is exactly why it’s worth keeping.
Healthcare context
#291 of 440 scored Healthcare companies, ranked by Moat Score.
Nearest peers by Moat Score
- #289SNOA SONOMA PHARMACEUTICALS, INC.36.1 out of 100, No moatNo moat
- #290RGNX REGENXBIO Inc.36.1 out of 100, No moatNo moat
- #292TELA TELA Bio, Inc.35.8 out of 100, No moatNo moat
- #293STEX STREAMEX CORP.35.7 out of 100, No moatNo moat
Compare TNDM with its nearest peers →All Healthcare companies on the Index →
Common questions about TNDM
- Does Tandem Diabetes Care, Inc. have an economic moat?
- Based on its FY2025 SEC filings, the Moat Index scores Tandem Diabetes Care, Inc. (TNDM) 35.9 out of 100 — below the Shallow-moat bar, so no moat. The four filters behind that score (each 0–100): pricing power 72, returns on capital 0, balance-sheet safety 28, capital discipline 44.
- How has TNDM's Moat Score changed over time?
- The record logs 3 readings since Jul 17, 2026; the latest reads 35.9 out of 100 (no moat). No tier changes on record yet. The history is append-only — readings are only ever added, never rewritten.